A trial looking at everolimus and exemestane for breast cancer (4EVER UK)

This trial is looking at everolimus (Afinitor) in combination with exemestane for breast cancer that has spread to surrounding tissues (locally advanced) or to another part of the body (advanced breast cancer). This trial is open to post menopausal women who have hormone receptor positive breast cancer (ER positive or PgR positive).

We know from research that everolimus with exemestane works for women with advanced hormone positive breast cancer. The researchers want to find a way to work out how well the treatment has worked.

To do this they will take samples of blood and tissue from women having everolimus and exemestane. They will look for substances (chemicals) that change the way a gene behaves or the way a cell looks and acts. These are called epigenetic markers.

The main aim of this trial is to look at how well women with advanced and locally advanced hormone positive breast cancer respond to treatment with everolimus and exemestane. They also want to see if there is a connection between the response to treatment and epigenetic markers.